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EFV/FTC/TDF for first-line HIV treatment. In scenario analysis assuming 
equivalent efficacy, EFV/FTC/TDF dominated EVG/cobi/FTC/TDF with lower costs 
and greater QALYs.  
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COST-EFFECTIVENESS EVALUATION OF LINEZOLID, VANCOMYCIN AND 
TEICOPLANIN IN TREATING NOSOCOMIAL PNEUMONIA CAUSED BY 
METHICILIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) – PUBLIC  
HEALTH CARE SYSTEM PERSPECTIVE  
Fujii RK1, Hájek P2, Lanzara GDA1, Manfrin DF1, Mould J3 
1Pfizer, Inc., São Paulo, Brazil, 2Pfizer, Praha, Czech Republic, 3Pfizer, New York, NY, USA  
OBJECTIVES: The objective of this research is to evaluate the cost-effectiveness 
of linezolid 600mgBID(LI), vancomycin 1gBID(VA) and teicoplanin 400mgBID(TE) 
in the treatment of nosocomial pneumonia caused by MRSA under the public 
health care system perspective. METHODS: To compare the options, a decision 
tree model was built considering an arm per treatment option, from which 
patients could respond to the initial treatment and continue to a maintenance 
treatment using the same antibiotics, or do not respond, and repeat the 
treatment with assumed 50% chance to use one of the other two antibiotics. 
Clinical or microbiological effectiveness could be used as determinants of 
response. Effectiveness measures were mortality, clinical and microbiological 
responses, calculated by an indirect comparison of a literature systematic 
review. Hospitalization days were evaluated. Only direct costs were considered, 
and were obtained from DATASUS/SIGTAP 2012 for medical procedures,  
and DATASUS/BPS considering the average of purchases from November 2011 to 
October 2012 for medications and materials, as the latest data available. Values 
were represented in 2012USD. A time horizon of 1 year was considered. 
RESULTS: Clinical response rates were 66.5%(VA), 68.3%(TE), 72.6%(LI), 
microbiological response rates were 56.1%(VA), 55.9%(TE), 64.4%(LI), mortality 
rates were 15.74%(VA), 13.56%(TE), 10.13%(LI). If clinical response was considered 
as a determinant of success, the treatment costs would be 13,806.58USD(VA), 
14,279.01USD(TE), 15,301.44USD(LI), hospitalization days would be 41(VA),  
39(TE), 26(LI), and if microbiological response was considered, the treatment 
costs would be 14,637.39USD(VA); 15,169.33USD(TE), 15,793.21USD(LI) and 
hospitalization days would be 42(VA), 40(TE), 28(LI). Incremental cost-
effectiveness ratios for TE and LI when compared to VA for clinical response 
were 26,246.03USD, 24,505.90USD, and for microbiological response were  
-26,597.03USD(dominated), 13,925.46USD respectively. CONCLUSIONS: Assuming 
a willingness to pay of 32,621.93USD (3 times Brazilian 2011GDP per capita), 
linezolid was the most cost-effective option compared to vancomycin, 
additionally presenting lower mortality and less hospitalization days at public 
health care services.  
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OBJECTIVES: Clinically, interferon-alpha (IFN-α) is used for inhibiting hepatitis B 
and C virus infection, but IFN-α treatment may cause side effects of depression. 
Recent study has reported that serum serotonin levels are associated with 
antiviral therapy outcomes in patients with chronic hepatitis C. The aim of this 
study was to evaluate the cost and effectiveness of antidepressants in hepatitis C 
patients treated with interferon. METHODS: This is a retrospective study from 
January 1, 2002 to December 31, 2010 using Chi-Mei Medical Center claim data. 
Subjects were divided into exposure and control groups. The exposure group 
included patients treated with IFN-α or combined antiviral drugs and 
antidepressants for at least 6 months. The control group was those without 
antidepressant treatment. The endpoints were evaluated liver related lab data, 
the number of visits to the out-patient department, emergency department or 
admission during treatment, and the cost. RESULTS: There were a total of 135 
patient diagnosed hepatitis B or C and treated with IFN-α or combined antiviral 
drugs. Comparing the exposure and control groups, the control group had a 
higher SGOT (53.97±40.0 vs. 93.16±64.54 IU/L, 95% CI=28.12~50.3, P<0.05); SGPT 
(62.07±5. IU/L vs. 316.36±123.4 IU/L, 95% CI=79.95~122.64, P<0.05), AFP (9.8±22.4 
ng/mL vs. 11.79±18.1 ng/mL, 95% CI=-1.77~5.7, P=0.304). Comparing mean health 
care costs in six months is NT 263,200 for exposure group and 242,600 for control 
group. No significant difference. That may be related to psychiatric visits and 
medication use. CONCLUSIONS: These results suggest that antidepressants may 
play an important role in hepatitis B or C patients treated with IFN-α or 
combined antiviral drugs. Future studies are needed to further clarify the 
mechanisms of antidepressant action.  
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OBJECTIVES: A pneumococcal 7-valent conjugate vaccine (PCV7) was launched 
as a Category II vaccine requiring out-of-pocket payment in China in 2008. The 
objective of this study was to estimate the expected health benefits, cost, and 
incremental cost-effectiveness of introducing a public financed City 
Immunization Program (CIP) to pay for PCV7 from a social perspective in the long 
term. METHODS: A Markov cohort model was used to estimate cost and 
epidemiological burden of invasive pneumococcal disease (IPD), pneumonia and 
otitis media for all age cohort in Beijing, Guangzhou, Shenzhen and Wuhan 
within five years. Data includes cost data from eight hospitals in four cities as 
well as epidemiological data from Bureau of National Health Insurance in 
Taiwan. Outcomes were measured by reduction in disease burden, cost, quality-
adjusted life years (QALYs) and incremental cost-effectiveness ratio. In addition 
we performed sensitivity analyses for key parameters. RESULTS: Due to this 
immunization program, 11793 people may avoid dying, 42265.49 QALYs were 
generated additionally in the four cities within five years. Besides, this program 
may reduce the disease burden about RMB 1,574.7 per person. CONCLUSIONS: 
Integrating PCV7 into CIP has remarkable cost-effectiveness. It would possibly 
bring more net benefit with the increasing rate of immunization.  
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OBJECTIVES: Streptococcus pneumoniae is an important gram-positive pathogen 
with more than 90 serotypes, responsible for invasive pneumococcal diseases 
(IPD) (meningitis, bacteremia) and noninvasive diseases (pneumonia, otitis acute 
middle [OAM]). This analysis is aimed to estimate the cost-effectiveness of 
pneumococcal conjugate vaccines PCV13 and PCV10 in terms of prevention of 
diseases and deaths by IPD, radiologically confirmed pneumonia, AOM, and life 
years gained (LYG) in a cohort of newborns in Colombia. METHODS: A decision 
tree was developed with national data including the distribution of 
pneumococcal serotypes in Colombia between 2009 and 2011. Comparators were: 
PCV13, PCV10 (scheme 2 + 1) against no vaccination; vaccine coverage of 90 % 
was assumed (699,975 children). The simulation of newborns in Colombia took 
place within a time horizon of 5 years and a discount rate of 3%. The analysis 
used the third-party payer perspective. The efficacy values of the vaccines were 
determined by a systematic review. Medical costs are expressed in 2012 US$ and 
were provided by “SURA” a Colombian health insurance company. Probabilistic 
sensitivity analyses for epidemiological, efficacy and cost parameters were 
performed. RESULTS: After 5 years of follow-up, PCV13 would prevent 426 deaths 
due to pneumococcal infections versus 331 that would be prevented by PCV10, 
compared to no vaccination. PCV13 and PCV10 would generate 25,212 LYG and 
19,584 LYG, respectively. Medical costs avoided would be US$19,920,837 and 
US$15,094,775, respectively. Compared to no vaccination, PCV13 and PCV10 were 
cost-effective, with cost-effectiveness ratio of US$570.35 and US$768.57 per LYG; 
although, PCV13 was dominant over PCV10 due to lower total costs and better 
health outcomes. CONCLUSIONS: PCV13 is a cost-saving strategy compared with 
PCV10, as part of a mass vaccination program in Colombian children under one 
year. PCV13 is expected to lead to a greater decrement in infant mortality from 
pneumococcal diseases.  
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OBJECTIVES: In 2012, the U.S. Advisory Committee on Immunization Practices 
(ACIP) revised their 1997 adult pneumococcal vaccination recommendations to 
include a sequential regimen of 13-valent pneumococcal conjugate vaccine 
(PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) for 
certain high-risk adults with immunocompromising conditions, while 
continuing routine PPSV23 use for healthy and immunocompetent adults with 
comorbidities. This study aims to examine: 1) cost-effectiveness of the 2012 ACIP 
recommendations relative to 1997 recommendations; 2) cost-effectiveness of 
potential future pneumococcal vaccination policies; 3) key assumptions that 
influence study results. METHODS: A static cohort model that incorporated 
costs, health outcomes, and quality-adjusted life-year (QALY) losses associated 
with invasive pneumococcal disease and non-bacteremic pneumococcal 
pneumonia (NBPP) was developed to evaluate the cost-effectiveness of seven 
pneumococcal vaccination strategies for an adult cohort 50 years of age using 
incremental cost-effectiveness ratios (ICERs). RESULTS: For aim 1, the 2012 ACIP 
recommendation was found to be the most economically efficient strategy (ICER 
of $14,781 per QALY gained). For aim 2, when the set of strategies evaluated was 
broadened to consider potential future policies, the most economically efficient 
strategy was modifying the 2012 recommendation for adults with 
immunocompromising conditions to include a sequential regimen of PCV13 and 
PPSV23 (ICER of $13,775 per QALY gained). For aim 3, cost-effectiveness ratios for 
alternative vaccination strategies were highly influenced by assumptions about 
vaccine effectiveness in NBPP and accounting for herd protection effects of 
pediatric pneumococcal vaccination on adult pneumococcal disease. 
CONCLUSIONS: Extending the 2012 ACIP recommendation to include a 
sequential regimen of PCV13 and PPSV23 at age 65 for adults with 
immunocompromising conditions appears to be a cost-effective vaccination 
policy. Given the uncertainty in available data and absence of key influential 
data related to vaccine effectiveness and herd protection, policy-makers should 
conduct comprehensive sensitivity analyses when evaluating new 
pneumococcal vaccine strategies in adults.  
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CHRONIC HEPATITIS C, GENOTYPE 1 IN THE ERA OF DIRECT ANTIVIRAL 
AGENTS: IS IT TIME TO SKIP THE BIOPSY AND TREAT EVERYONE?  
Singer ME1, Mir HM2, Younossi ZM2 
1Case Western Reserve University School of Medicine, Cleveland, OH, USA, 2Inova Fairfax 
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OBJECTIVES: Guidelines for management of genotype 1 chronic hepatitis C (CH-
C) patients recommend a liver biopsy and treating patients with significant 
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histologic fibrosis. Advances in therapy with direct acting antivirals have led to 
improvements in treatment success. The objective of this study was to assess if 
it is now cost-effective to treat all CH-C genotype 1 patients regardless  
of histologic fibrosis stage. METHODS: A decision analytic Markov model 
simulating patients until death was used to compare two strategies for treating 
CH-C genotype 1: Triple therapy with biopsy (TT) or treat all (TTA). For TT, 
patients with moderate or advanced fibrosis were treated; others were biopsied 
every 5 years until age 70. Triple therapy consisted of telaprevir for 12 weeks, 
along with double-therapy (pegylated-interferon and ribavirin) for 24 or 48 weeks 
depending on response. The reference case was a treatment-naïve 50-year-old. 
Parameters were taken from the literature, Medicare fee schedule and  
drug acquisition cost. Effectiveness was measured in quality-adjusted life 
years(QALYs), and disease progression. Strategies were compared on the basis of 
cost, effectiveness and the incremental cost-effectiveness ratio (ICER, in $/QALY). 
Cost and effectiveness were discounted at 3% annually. RESULTS: For TT, 58% 
were treated initially and 25% were treated later. TTA led to less disease 
progression: Decompensated cirrhosis (11.8% vs. 13.4%), liver cancer (10.5% vs. 
12.0%), and liver transplant (4.6% vs. 5.2%). TTA was more expensive, $103,135 vs. 
$90,904, but more effective, 17.195 vs. 16.383 QALYs. TTA was very cost- 
effective with an incremental cost-effectiveness ratio of just $15,063/QALY. 
CONCLUSIONS: The recommendation to treat CH-C genotype 1 patients  
with moderate and advanced fibrosis, and monitor those with mild fibrosis, 
must be reassessed with increasingly more effective anti-HCV therapy.  
Treating everyone may be even more cost-effective for newer, more  
effective treatments with less side effects and shorter regimens (e.g. oral agents 
only).  
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OBJECTIVES: Current influenza vaccination practice using trivalent inactivated 
vaccine (TIV) and trivalent live attenuated influenza vaccine (LAIV) covers only 
one of two commonly circulating influenza B lineages; mismatch and co-
circulation are frequent and unpredictable. We evaluated the health outcomes 
and cost-effectiveness of universal vaccination with QIV compared with current 
vaccination practice. METHODS: We used a 1-year decision-tree from a societal 
perspective, including influenza-associated productivity losses and death. US 
Population was stratified to model age-specific (< 5, 5-17, 18-49, 50-64, and 65+) 
vaccination coverage, vaccine efficacy and risks of influenza complications. 
Rates of influenza, health care utilization, disease-related costs, and survival 
were estimated from published data where possible. Annual cases, lifetime costs 
(2011 USD) and quality adjusted life years (QALYs) lost were calculated and 
discounted (3% per annum) appropriately. We conducted one-way and 
probabilistic sensitivity analyses. RESULTS: Results suggest that vaccination 
with QIV instead of TIV/LAIV is expected to yield 77,817 fewer medically-
attended influenza cases, approximately 4,360 fewer related hospitalizations and 
868 fewer deaths per year. QIV vaccination is expected to result in approximately 
4,342 fewer QALYs lost compared with TIV/LAIV. The model projects QIV to  
be cost-effective at $50,000/QALY, excluding death-related productivity losses, 
avoiding double counting as death-related QALYs are included, at a price 
increment of 35% over the average weighted TIV price. The increase  
in vaccination costs ($385 million) is offset by a $411 million reduction in 
influenza-related treatment costs, comprising $142 million in direct medical 
costs (physician visits, antivirals, and outpatient and inpatient care) and $269 
million in direct non-medical cost savings. Results were robust in sensitivity 
analyses. CONCLUSIONS: Under the model assumptions, a strategy of 
vaccination with a quadrivalent influenza vaccine is expected to be a cost-
effective alternative to current practice, by reducing the costs as well as cases, 
hospitalizations and deaths associated with vaccine-mismatched influenza B 
disease.  
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OBJECTIVES: To adapt an existing and previously published economic (micro-
simulation model) in HIV (ARAMIS) to evaluate the cost-effectiveness of 
maraviroc (MVC) in the US in treatment naïve HIV-patients based on the MERIT 
(Maraviroc versus Efavirenz in Treatment-Naive Patients) study. METHODS: MVC 
was compared to efavirenz (EFV) in treatment naïve patients with CCR5-tropic 
HIV. Efficacy and safety data were based on the post hoc analysis in the MERIT 
study in patients rescreened with an Enhanced Sensitivity Trofile Assay (ESTA). 
ARAMIS-MVC is a microsimulation Markov model, has a lifetime analytic time 
horizon with a monthly cycle length. Health states are defined in terms of 
chronic and acute HIV/AIDS. Treatment algorithms were updated based on 
guidelines and expert opinion. Long-term non-AIDS diseases (Cardiovascular, 
hepatic and renal diseases and non-AIDS defining cancer) were included in the 
model to reflect the higher prevalence of these illnesses in the HIV population 
and depended on age, CD4-cell count and hepatic status. Costs included 
antiretroviral treatment costs, HIV care, testing, adverse event (gastrointestinal 
events, rash, neuropsychiatric adverse events) and non-AIDS disease costs, at 
the 2012 level. The cohort of the model used the population included in the 
MERIT study and 1,000,000 simulations were used for the model. RESULTS: The 
ARAMIS-MVC model indicates that MVC compared to EFV over a life time is 
associated with some additional quality-adjusted life years (QALY) (0.092 
difference) but with some additional total costs ($8,900 additional costs for MVC). 
The incremental cost effectiveness ratio for MVC compared to EFV is $96,000 per 
QALY gained. Life expectancy with MVC was slightly higher than EFV (2.7 
months difference). CONCLUSIONS: MVC is a cost-effective treatment option for 
CCR5 tropic treatment-naïve patients in the US considering a threshold of 
$100,000/QALY.  
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OBJECTIVES: Current guidelines for the treatment of acute bacterial skin and 
skin structure infections (ABSSSI) recommend treatment pathways based on the 
infection types and severity. However, few studies have attempted to establish 
the health care resource utilization and costs overall and in various treatment 
settings, e.g., ED visits, in-patient, outpatient visit and/or treatment (e.g. infusion 
center), and outpatient pharmacy, using real world data. METHODS: The medical 
and pharmacy administrative claims of adult ABSSSI subjects with continuous 
commercial or Medicare Advantage enrollment with Part D prescription drug 
coverage (MAPD) between 01 January 2009 and 31 December 2011 were extracted 
from a large national health plan affiliated with OptumInsight. Subjects were 
grouped based on their initiation of five MRSA-active antibiotics: linezolid, 
vancomycin, daptomycin, clindamycin, or tigecycline. Health care resource 
utilization and costs were assessed for each treatment group. RESULTS: After 
applying inclusion and exclusion criteria, 8,332 commercial and 4,218 MAPD were 
included in the study. The average age was 50 years for commercial enrollees 
and 69 years for MAPD enrollees. The Quan-Charlson comorbidity index varied 
among treatment groups and, a majority of the clindamycin treatment subjects 
had few or no comorbidities. The average ABSSSI-related total health care cost, 
per patient per month, was $18,290 including $7,261(39.7%) for inpatient cost, 
$825(4.5%) for ED visits, $2,447 (13.4%) for outpatient treatment/visits, 
$1233(6.7%) for pharmacy claims, $971(5.3%) for office visits, and $5553 (30.4%) 
for other medical cost. The costs overall and in various treatment settings varied 
by initial antibiotic choices and insurance plans. CONCLUSIONS: Inpatient 
treatment remains the largest component of total ABSSSI treatment cost. To 
minimize the burden on the health care system, there is an urgent need to 
develop new antibiotics that prevent or decrease the number of hospitalizations 
and reduce the length of inpatient stays.  
 
PIN82  
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OBJECTIVES: Boceprevir is indicated for the treatment of chronic hepatitis C 
virus (HCV) genotype 1 in combination with peginterferon-alpha and ribavirin 
(PEGATRON). Boceprevir plus PEGATRON has been shown to significantly 
increase sustained virologic response (SVR) rates in naive and previously treated 
adults with chronic hepatitis C (CHC) genotype 1, compared to PEGATRON 
alone.This analysis is to determine the cost-effectiveness of PEGATRON with 
boceprevir compared to PEGATRON alone in treatment-naive and treatment-
experienced patients in Australia. METHODS: A semi-Markov model was 
constructed to capture the early stages of CHC and the possibility of SVR, as well 
as important downstream health states which impact on quality of life, survival 
and resource utilisation. Early stages of liver disease were defined by levels F0 to 
F3 of METAVIR scoring system. Advanced stages were defined as compensated 
cirrhosis, decompensated cirrhosis, and primary hepatocellular carcinoma. 
Patients who moved from a baseline fibrosis score of F0-F3 to SVR were assumed 
to be free of any further disease progression, remaining in a viral-negative state 
until death. Patients who moved from a baseline fibrosis score of F4 to SVR were 
assumed to retain some risk of liver complications due to pre-existing liver 
damage. Subjects who failed to achieve SVR were assumed to be at risk of 
disease progression until death. Costs and preference-based utility values varied 
by health state, and were aggregated over the patients’ lifetimes to calculate an 
incremental cost-utility ratio. RESULTS: The base case incremental cost-utility 
ratio was AU$38,712 per additional QALY in the treatment-naïve population, and 
AU$33,750 in the treatment-experienced population. The model was robust to 
variations in the SVR rate and model duration. CONCLUSIONS: The use of 
boceprevir for untreated chronic genotype 1 HCV is a cost-effective option for 
adult patients with CHC genotype 1.  
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